Komori
Governance4527ROHTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

The Board of Directors’ Opinion on the Shareholder Proposal

The Board of Directors decided to oppose all 8 shareholder proposals submitted by 2 shareholders. The proposals cover the dismissal of directors, establishment of a strategic review committee, shareholder returns, share-based compensation, the proportion of outside directors, disclosure of the cost of capital, and changes to the record date for the General Meeting of Shareholders.

Worth reading
80Important
Scored from 3 of 5 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Governance structure

Controlling shareholder
The company has not disclosed whether a controlling shareholder or parent company exists.

When one company holds most of the voting rights, its wishes are more likely to prevail in management. How the interests of minority shareholders are protected is a key issue.

Number of directors14 directors, including 5 outside directors (FY2025). The document also refers to the 15-director limit under the Articles of Incorporation.
Committee2
Nomination Committee (a majority of the members are independent outside directorsand the chair is also an independent outside director) and Compensation Committee (a majority of the members are independent outside directors). The proportion of outside committee members is not disclosed as a specific figure.
Changes this time

The Board of Directors resolved to oppose all agenda items under Shareholder Proposal 1 and Shareholder Proposal 2. The document describes the existing review framework operated by the Nomination Committee and Compensation Committee.

Governance structure
ItemDetails
Number of directors14 directors, including 5 outside directors (FY2025). The document also refers to the 15-director limit under the Articles of Incorporation.
CommitteeNomination Committee (a majority of the members are independent outside directors, and the chair is also an independent outside director) and Compensation Committee (a majority of the members are independent outside directors). The proportion of outside committee members is not disclosed as a specific figure.
Controlling shareholderThe company has not disclosed whether a controlling shareholder or parent company exists.
Changes this timeThe Board of Directors resolved to oppose all agenda items under Shareholder Proposal 1 and Shareholder Proposal 2. The document describes the existing review framework operated by the Nomination Committee and Compensation Committee.
Items this document does not state (4)
Corporate Governance StructureNumber of independent officersPolicy on cross-shareholdingsTakeover defenses

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The Board explained that, to enhance corporate value and the common interests of shareholders, it is appropriate to consider each matter comprehensively and flexibly within the existing framework of the Board of Directors, Nomination Committee, and Compensation Committee. Specifically, it stated that the proposed mandatory establishment of a committee, proportion of outside directors, amount of treasury share acquisitions, and changes to disclosure obligations and the record date under the Articles of Incorporation could obscure the allocation of responsibility or impair management flexibility and agility.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
The Board of Directors’ Opinion on the Shareholder Proposal | ROHTO PHARMACEUTICAL CO.,LTD. (4527) timely disclosure | Komori